Monte Rosa Therapeutics, Inc. logo GLUE - Monte Rosa Therapeutics, Inc.

NEXT EARNINGS: Mar 19, 2026 (in 22 days) EPS Est: $-0.45
Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 7
HOLD 2
SELL 0
STRONG
SELL
0
| PRICE TARGET: $31.75 DETAILS
HIGH: $37.00
LOW: $22.00
MEDIAN: $34.00
CONSENSUS: $31.75
UPSIDE: 65.28%
Market Cap: 1.25B
Volume: 681,673
Avg Volume: 1,608,721
52 Week Range: 3.5-25.77
Sector: Healthcare
Industry: Biotechnology
Beta: 1.62
Last Dividend: $N/A
Exchange: NASDAQ
Country: US
Employees: 142
IPO Date: 2021-06-24
EPS (TTM): -0.98
P/E Ratio: -7.06
Revenue (TTM): 75.62M
Total Assets: 438.73M
Total Debt: 42.72M
Cash & Equiv: 224.25M
Rev Growth (5Y): N/A
EPS Growth (5Y): N/A
FCF Growth (5Y): N/A
ROCE: -28.8%
Debt/Equity: 0.19

Earnings History

Date EPS Actual EPS Est EPS Surprise Rev Actual Rev Est Rev Surprise
2025-11-06 $-0.33 $-0.39 +15.4% $12.8M $15.5M -17.7%
2025-08-07 $-0.15 $-0.31 +51.6% $23.2M $7.8M +198.4%
2025-05-08 $0.57 $-0.24 +337.5% $84.9M $13.6M +526.0%
2025-03-20 $0.23 $-0.37 +162.2% $60.6M $46.7M +30.0%
2024-11-07 $-0.29 $-0.45 +35.6% $9.2M $2.6M +249.3%
2024-08-08 $-0.43 $-0.50 +14.0% $4.7M $1.3M +248.1%
2024-05-09 $-0.53 $-0.56 +5.4% $1.1M $1.4M -24.0%
2024-03-14 $-0.58 $-0.57 -1.8% $8.8M $3.5M +148.1%

Track Record

Statements >
Metric 2024 2023 2022 2021 2020 2019
Revenue 75.62M 0 0 0 0 0
Net Income (72.70M) (135.35M) (108.50M) (73.96M) (35.88M) (8.02M)
EPS -0.98 -2.63 -2.30 -1.59 -0.82 -0.18
Total Assets 438.73M 303.75M 342.39M 366.33M 49.38M 11.09M
Total Debt 42.72M 46.04M 47.00M 0 67.76M 750,000
Cash & Equivalents 224.25M 128.10M 54.91M 346.07M 41.70M 6.00M
Operating Cash Flow 42.00M (43.80M) (92.47M) (59.36M) (23.05M) (6.17M)
Free Cash Flow 38.01M (62.84M) (105.38M) (69.09M) (26.44M) (7.56M)
FCF per Share 0.51 -1.22 -2.23 -1.48 -0.60 -0.17
Book Value 222.94M 179.25M 271.41M 347.51M (48.73M) (12.15M)
Cash & ST Investments 372.15M 232.41M 262.83M 346.07M 41.70M 6.00M
ROC Equity -0.33 -0.76 -0.40 -0.21 N/A N/A